NCCN Curtain Raiser

by | Mar 27, 2024 | LM

❗Mark Your Calendars❗ Plus Therapeutics will be presenting a poster at the National Comprehensive Cancer Network Annual Conference Press release: https://bit.ly/PSTV_PR...

Susan G. Komen: LM

by | Mar 26, 2024 | LM

Thank you to @SusanGKomen for adding “Leptomeningeal Metastasis” to your Breast Cancer Glossary patient resource! 🎗️ “Leptomeningeal Metastasis: Cancer that spreads from the original tumor to the meninges (the thin layers of tissue that cover and...

CSF-01 Announcement

by | Mar 25, 2024 | LM

BREAKING NEWS: Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic > Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and...

LM Cohort 5 Completion

by | Mar 11, 2024 | LM

BREAKING NEWS! We have completed dosing in Cohort 5 of our ongoing ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases, with a total of 18 patients have been dosed in the trial to date. The trial is STILL ENROLLING and accepting new...

Miami Breast Conference

by | Mar 6, 2024 | LM

Some of our clinical team will be attending the #MiamiBreast Cancer Conference this week, as it relates to our Leptomeningeal Metastases clinical trial for Metastatic Breast Cancer patients. If you are interested in connecting with the team there, send us a DM. See...

LM Patient Study Guide

by | Feb 15, 2024 | LM

⭐ We have a NEW Patient Guide for our Leptomeningeal Metastases trial available NOW on our website at ReSPECT-Trials.com! Please share this resource with caregivers and patients that may be interested in enrolling for our Phase 1 ReSPECT-LM clinical trial. #BrainMets...